Population Pharmacokinetic Evaluation with External Validation of Tacrolimus in Chinese Primary Nephrotic Syndrome Patients

被引:4
|
作者
Yang, Lin [1 ]
Yang, Nan [2 ]
Yi, Bin [1 ]
Pei, Qi [2 ]
Huang, Zhijun [1 ,3 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Dept Nephrol, Changsha 410013, Peoples R China
[2] Cent South Univ, Xiangya Hosp 3, Dept Pharm, Changsha 410013, Peoples R China
[3] Cent South Univ, Xiangya Hosp 3, Ctr Clin Pharmacol, Changsha 410013, Peoples R China
基金
中国国家自然科学基金;
关键词
External evaluation; Individualized drug administration; Population pharmacokinetics; Primary nephrotic syndrome; Tacrolimus; KIDNEY; CONCLUSIONS; MANAGEMENT;
D O I
10.1007/s11095-022-03273-3
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose The generalizability of numerous tacrolimus population pharmacokinetic (popPK) models constructed to promote optimal tacrolimus dosing in patients with primary nephrotic syndrome (PNS) is unclear. This study aimed to evaluate the predictive performance of published tacrolimus popPK models for PNS patients with an external data set. Methods We prospectively collected 223 concentrations from 50 Chinese adult patients with PNS who were undergoing tacrolimus treatment. Data on published tacrolimus popPK models for adults and children with PNS were extracted from the literature. Model predictability was evaluated with prediction-based and simulation-based diagnostics and Bayesian forecasting. Results In prediction-based evaluation, none of the 11 identified published popPK models of tacrolimus had met a predefined criteria of a mean prediction error <= +/- 20%, and the prediction error within +/- 30% of the identified models didn't exceed 50%. Simulation-based diagnostics also indicated unsatisfactory predictability. Bayesian forecasting demonstrated amelioration in the model predictability with the inclusion of 2-3 prior observations. Moreover, the predictive performance of nonlinear models was not better than that of one-compartment models. Conclusions The prediction of tacrolimus concentrations for patients with PNS remains challenging; published models are not applicable for extrapolation to other hospitals. Bayesian forecasting significantly improved model predictability and thereby helped to individualize tacrolimus dosing.
引用
收藏
页码:1907 / 1920
页数:14
相关论文
共 50 条
  • [1] Population Pharmacokinetic Evaluation with External Validation of Tacrolimus in Chinese Primary Nephrotic Syndrome Patients
    Lin Yang
    Nan Yang
    Bin Yi
    Qi Pei
    Zhijun Huang
    Pharmaceutical Research, 2022, 39 : 1907 - 1920
  • [2] Dosage Optimization Based on Population Pharmacokinetic Analysis of Tacrolimus in Chinese Patients with Nephrotic Syndrome
    Lu, Tong
    Zhu, Xu
    Xu, Shansen
    Zhao, Mingming
    Huang, Xueshi
    Wang, Zhanyou
    Zhao, Limei
    PHARMACEUTICAL RESEARCH, 2019, 36 (03)
  • [3] Dosage Optimization Based on Population Pharmacokinetic Analysis of Tacrolimus in Chinese Patients with Nephrotic Syndrome
    Tong Lu
    Xu Zhu
    Shansen Xu
    Mingming Zhao
    Xueshi Huang
    Zhanyou Wang
    Limei Zhao
    Pharmaceutical Research, 2019, 36
  • [4] Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model
    Huang, Lingfei
    Liu, Yixi
    Jiao, Zheng
    Wang, Junyan
    Fang, Luo
    Mao, Jianhua
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 143
  • [5] External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients
    Zhao, Chen-Yan
    Jiao, Zheng
    Mao, Jun-Jun
    Qiu, Xiao-Yan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 81 (05) : 891 - 907
  • [6] Tacrolimus Population Pharmacokinetic Model in Adult Chinese Patients with Nephrotic Syndrome and Dosing Regimen Identification Using Monte Carlo Simulations
    Liao, Minghao
    Wang, Minglu
    Zhu, Xu
    Zhao, Limei
    Zhao, Mingming
    THERAPEUTIC DRUG MONITORING, 2022, 44 (05) : 615 - 624
  • [7] External evaluation of tacrolimus population pharmacokinetic models in adult lung transplant patients: How to enhance the predictive ability of the model?
    Han, Lu
    Cui, Yifan
    Pan, Yan
    Chen, Rui
    Jiao, Zheng
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 143
  • [8] Systematic external evaluation of published population pharmacokinetic models for tacrolimus in adult liver transplant recipients
    Cai, Xiaojun
    Li, Ruidong
    Sheng, Changcheng
    Tao, Yifeng
    Zhang, Quanbao
    Zhang, Xiaofei
    Li, Juan
    Shen, Conghuan
    Qiu, Xiaoyan
    Wang, Zhengxin
    Jiao, Zheng
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 145
  • [9] Population pharmacokinetics and dosage optimization of tacrolimus in pediatric patients with nephrotic syndrome
    Wang, Xiaoqing
    Hang, Ye
    Chen, Chaoyang
    Ma, Lingyue
    Xiao, Huijie
    Zhou, Ying
    Cui, Yimin
    Wang, Fang
    Su, Baige
    Yao, Yong
    Ding, Jie
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, 57 (03) : 125 - 134
  • [10] Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients
    Chen, Yu-si
    Liu, Zi-qi
    Chen, Rong
    Wang, Lei
    Huang, Ling
    Zhu, Xiao
    Zhou, Tian-yan
    Lu, Wei
    Ma, Ping
    ACTA PHARMACOLOGICA SINICA, 2017, 38 (08) : 1195 - 1204